PR Newswire
MISSISSAUGA, Ontario, Dec. 19, 2016
MISSISSAUGA, Ontario, Dec. 19, 2016 /PRNewswire/ -- Aralez Pharmaceuticals
Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that it has been added to the
NASDAQ Biotechnology Index (NASDAQ: NBI) effective as of the opening of trading on Monday, December 19,
2016.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified
as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. These companies must meet
eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria.
The NASDAQ Biotechnology Index is re-ranked annually and is the basis for the iShares NASDAQ Biotechnology Index Fund,
which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the
NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various
exchanges. For more information about the NASDAQ Biotechnology Index visit www.nasdaq.com.
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on
delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and
commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in
Mississauga, Ontario, Canada, its U.S. Headquarters is planned to be in Princeton, NJ and the Ireland Headquarters is in Dublin, Ireland. More
information about Aralez can be found at www.aralez.com.
Aralez Pharmaceuticals US Inc. Contact:
Nichol L. Ochsner
Executive Director, Investor Relations & Corporate Communications
732-754-2545
nochsner@aralez.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aralez-added-to-the-nasdaq-biotechnology-index-300381095.html
SOURCE Aralez Pharmaceuticals Inc.
